DXCM (DexCom) Total Stockholders Equity: $2,957 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is DexCom Total Stockholders Equity?

DexCom DXCM +1.50% Total Stockholders Equity is $2,957 Mil as of Mar. 2026. The stock has 3 warning signs investors should review.

DexCom's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $2,957 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. DexCom's Book Value per Share for the quarter that ended in Mar. 2026 was $7.66. The ratio of a company's debt over equity can be used to measure how leveraged this company is. DexCom's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.47.

DexCom  (NAS:DXCM) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

DexCom's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(2956.9-0)/385.900
=7.66

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

DexCom's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(20.5 + 1364.3) / 2956.9
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexCom Total Stockholders Equity Related Terms

DexCom Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for DexCom's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexCom Total Stockholders Equity Chart

DexCom Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,042.10 2,131.80 2,068.60 2,102.60 2,746.00

DexCom Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,266.60 2,573.10 2,726.10 2,746.00 2,956.90
What does a Total Stockholders Equity of $2,957 Mil mean?
DexCom (DXCM) has a Total Stockholders Equity of $2,957 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for DexCom and its competitors.
Is DexCom's Total Stockholders Equity too high?
DexCom's current Total Stockholders Equity is $2,957 Mil.
How does DexCom's Total Stockholders Equity compare to GEHC and STE?
DexCom's Total Stockholders Equity of $2,957 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for DexCom and its competitors. DexCom's current Total Stockholders Equity is $2,957 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
Based on GuruFocus' analysis, DexCom (DXCM) is currently considered Significantly Undervalued. The stock's GF Value™ is $104.74, compared to a current price of $71.54 — trading 31.7% below its estimated fair value. The current Total Stockholders Equity is $2,957 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For DexCom (DXCM), the current Total Stockholders Equity is $2,957 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DexCom Business Description

Address 6340 Sequence Drive, San Diego, CA, USA, 92121
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.